(NASDAQ: SCYX) Scynexis's forecast annual revenue growth rate of -4.03% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Scynexis's revenue in 2026 is $20,601,000.On average, 5 Wall Street analysts forecast SCYX's revenue for 2026 to be $3,444,921,362, with the lowest SCYX revenue forecast at $3,309,857,934, and the highest SCYX revenue forecast at $3,546,263,597. On average, 5 Wall Street analysts forecast SCYX's revenue for 2027 to be $171,330,460, with the lowest SCYX revenue forecast at $164,630,885, and the highest SCYX revenue forecast at $176,377,473.
In 2028, SCYX is forecast to generate $813,328,381 in revenue, with the lowest revenue forecast at $655,620,390 and the highest revenue forecast at $972,018,976.